Pacific Biosciences of California, Inc. (PACB)
$
0.91
-0.01 (-1.10%)
Key metrics
Financial statements
Free cash flow per share
-0.7500
Market cap
336 Million
Price to sales ratio
2.1819
Debt to equity
1.3274
Current ratio
7.4764
Income quality
0.6650
Average inventory
62.2 Million
ROE
-0.5898
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Pacific Biosciences of California, Inc. specializes in designing, developing, and manufacturing sequencing systems aimed at unraveling genetically complex challenges. The gross profit ratio is 0.24 reflecting the efficiency of the company’s production and sales operations. The net total of other income and expenses is $46,846,000.00 shedding light on the company’s non-core financial activities. The EBITDA is -$242,785,000.00 a key indicator of the company's operational profitability, illustrating its performance in generating earnings. Furthermore, the weighted average number of shares outstanding is 274,488,000.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'PACB' in the market, making it easier for investors to track its performance. Pacific Biosciences offers a variety of products, including PacBio's Systems that conduct, monitor, and analyze biochemical sequencing reactions, along with consumables like single molecule real-time (SMRT) cells and reagent kits tailored for specific workflows. Their market outreach extends to research institutions, clinical laboratories, genome centers, and pharmaceutical companies, among others. The stock is affordable at $0.91 suitable for budget-conscious investors looking for opportunities in the market. With a high average trading volume of 8,556,353.00 the stock indicates strong liquidity, allowing for easier buying and selling. With a market capitalization of $273,137,367.00 the company is classified as a small-cap player, positioning it uniquely within the industry landscape. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape and driving innovation forward. Additionally, it belongs to the Healthcare sector, where its advancements foster growth and enhance competitive dynamics. The company also maintains a development and commercialization agreement with Invitae Corporation, further expanding its market presence.
Is Pacific Biosciences of California, Inc. (PACB) a good investment?
Investing in Pacific Biosciences of California, Inc. (PACB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Pacific Biosciences of California, Inc. (PACB)'s stock forecast?
Analysts predict Pacific Biosciences of California, Inc. stock to fluctuate between $0.91 (low) and $2.72 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Pacific Biosciences of California, Inc.'s market capitalization?
As of 2025-05-28, Pacific Biosciences of California, Inc.'s market cap is $273,137,367, based on 300,085,000 outstanding shares.
How does Pacific Biosciences of California, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Pacific Biosciences of California, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Pacific Biosciences of California, Inc. (PACB) stock?
To buy Pacific Biosciences of California, Inc. (PACB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PACB. Place an order (Market, Limit, etc.).
What is the best time to invest in Pacific Biosciences of California, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Pacific Biosciences of California, Inc. perform in the last earnings report?
Revenue: $154,014,000 | EPS: -$1.12 | Growth: -7.44%.
Where can I find Pacific Biosciences of California, Inc.'s investor relations reports?
Visit https://www.pacb.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Pacific Biosciences of California, Inc.?
You can explore historical data from here
What is the all-time high and low for Pacific Biosciences of California, Inc. stock?
All-time high: $53.69 (2021-02-11) | All-time low: $0.85 (2025-05-28).
What are the key trends affecting Pacific Biosciences of California, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
zacks.com
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
zacks.com
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day.
globenewswire.com
Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs
zacks.com
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day.
globenewswire.com
Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.
globenewswire.com
MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 342,432 shares of PacBio common stock to the Company's recently hired Chief Financial Officer, Jim Gibson, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on March 31, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
marketwatch.com
Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31.
zacks.com
Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.
See all news
